Genetic signals that predict progression from early myeloma conditions to active disease
Myeloma Defining Genomic Events to Differentiate Benign and Malignant Myeloma Precursor Conditions
['FUNDING_R37'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11331322
This project will look for genetic changes that help tell which people with early myeloma precursor conditions are likely to develop active multiple myeloma.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11331322 on ClinicalTrials.gov |
What this research studies
If I have an early myeloma condition like MGUS or smoldering myeloma, this project uses whole-genome sequencing of patient samples to find genetic events linked to later cancer. The team has already shown that bulk whole-genome sequencing can detect features such as chromothripsis, APOBEC mutational activity, and mutations in key driver genes that differ between stable and progressive cases. Because bulk sequencing can miss very small subclones that may drive progression, the project will apply more sensitive genomic analyses to better find those tiny cancer cell groups. The work aims to improve how we identify people who need closer monitoring or early prevention steps.
Who could benefit from this research
Good fit: Adults aged 21 and older with monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma are the ideal candidates for this research.
Not a fit: People without myeloma precursor conditions or those who already have symptomatic multiple myeloma are unlikely to receive direct benefit from this grant's risk-prediction focus.
Why it matters
Potential benefit: If successful, this work could allow doctors to identify high-risk patients earlier and offer closer monitoring or preventive interventions before symptomatic myeloma develops.
How similar studies have performed: Previous work, including the investigators' bulk whole-genome sequencing studies, has shown these genomic events can be detected, but reliably finding tiny subclones that drive progression remains a newer challenge.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAURA, FRANCESCO — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: MAURA, FRANCESCO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.